Predicting PD-L1 expression status in patients with non-small cell lung cancer using [(18)F]FDG PET/CT radiomics

BACKGROUND: In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the available ICI therapy strategies, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors are the most wide...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiaoqian, Zhao, Yan, Zhang, Jingmian, Zhang, Zhaoqi, Liu, Lihua, Zhao, Xinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868196/
https://www.ncbi.nlm.nih.gov/pubmed/36682020
http://dx.doi.org/10.1186/s13550-023-00956-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868196/
https://www.ncbi.nlm.nih.gov/pubmed/36682020
http://dx.doi.org/10.1186/s13550-023-00956-9

Ejemplares similares